Book a Meeting

Highly Galactosylated Anti-IL17A (Vunakizumab) Antibody (CAT#: BioBet-GA-290ZP) Datasheet

Target
IL17A
Isotype
IgG1, κ
Description
The Highly Galactosylated Anti-IL17A (Vunakizumab), a biobetter antibody contains with a high level of galactosylation.
Antibody Indication
Psoriatic arthritis (PSA)
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced IL17A antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
IL17A
Full Name
Interleukin 17A
Background
The protein encoded by this gene is a proinflammatory cytokine produced by activated T cells. This cytokine regulates the activities of NF-kappaB and mitogen-activated protein kinases. This cytokine can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO). High levels of this cytokine are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis. [provided by RefSeq, Jul 2008]
Alternative Names
Secukinumab; Cosentyx; 875356-43-7; AIN457; DB09029IL17A; interleukin 17A; CTLA8, IL17, interleukin 17 (cytotoxic T lymphocyte associated serine esterase 8); interleukin-17A; cytotoxic T lymphocyte associated protein 8; IL 17; IL 17A; CTLA-8;
Gene ID
3605
UniProt ID
Q16552
Cellular Localization
Extracellular region or secreted
Genecards
5981
Involvement in Disease
Its related pathways are PEDF Induced Signaling and Immune response IL-23 signaling pathway.
Related Pathways
Ligand for IL17RA and IL17RC. The heterodimer formed by IL17A and IL17F is the ligand of the heterodimer formed by IL17RA and IL17R. Participate in inducing stromal cells to produce pro-inflammatory and hematopoietic cytokines.
Function
Cancer antibody; Immune System antibody
Field of research
Found both in glycosylated and nonglycosylated forms
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
Vunakizumab
Host
Humanized
Species Reactivity
Human
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL17A. Vunakizumab is a humanized monoclonal antibody that can be potentially used in the treatment of Autoimmune diseases, Psoriasis.
Antibody Indication
Psoriatic arthritis (PSA)

Psoriatic arthritis (PSA)

Related Products

Non-fucosylated Anti-Human IL17A (Perakizumab) Therapeutic Antibody (CAT#: BioBet-292ZP)
Anti-IL17A Antibody, On-Target (CAT#: AES-0622-ZP809)
Highly Galactosylated Anti-IL17A (Perakizumab) Antibody (CAT#: BioBet-GA-292ZP)
Non-Fucosylated Anti-Human IL17A (ANB004) Therapeutic Antibody (CAT#: BioBet-1055ZP)
Anti-IL17A Antibody, Highly Galactosylated (CAT#: BioBet-GA-289ZP)
Highly Galactosylated Anti-IL17A (Bimekizumab) Antibody (CAT#: BioBet-GA-291ZP)
Anti-IL17A Antibody, FcγRIIB Binding Enhanced (CAT#: AES-0622-ZP481)
Anti-IL17A Antibody, Recycling (CAT#: AES-0622-ZP153)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.